CVS Health stock climbed Friday after an analyst predicted strong earnings growth in 2025, driven partly by its Medicare Advantage plans. TD Cowen analyst Charles Rhyee upgraded shares of CVS to Buy from Hold and increased his price target to $85 from $59. The company has struggled with higher medical costs in its insurance business.
Investing.com -- Analysts at TD Cowen have raised their rating of CVS Health (NYSE:CVS) to "Buy" from "Hold", citing changes to its 2025 Medicare Advantage plan benefits announced earlier this week.
CVS Health (CVS) reachead $62.92 at the closing of the latest trading day, reflecting a +1.09% change compared to its last close.